NCT06027853View on ClinicalTrials.gov

Natural Killer(NK) Cell Therapy Targeting CLL1 in Acute Myeloid Leukemia

PHASE1RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 10, 2023

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2026

Conditions
AML, Adult
Interventions
DRUG

CLL1 CAR-NK cell injection

"Drug: CLL1 NK cell therapy Drug: Cyclophosphamid Lympho-conditioning Agent Drug: Fludarabine Lympho-conditioning Agent~Drug: VP-16 Lympho-conditioning Agent"

Trial Locations (1)

Unknown

RECRUITING

Clinical research ethics committee of the first affiliated hospital, college of medicine, zhejiang University, Hangzhou

All Listed Sponsors
collaborator

Hangzhou Qihangene Biotech Co.,Ltd.

UNKNOWN

lead

Zhejiang University

OTHER